Amylyx Pharmaceuticals, Inc.

Good morning. My name is John and I'll be your conference operator today. At this time, I would like to welcome everyone to the MLX Parameciedicals second quarter earnings conference call. All participants will be in the listen only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question, please press star on your telephone keypad. To withdraw your question, please press star 2. Please limit your questions to one question with one follow-up. If you would like to add additional questions, you may rejoin the queue. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Lindsay Allen, Vice President, Investor Relations and Communications.

Please go ahead, ma

'am. Good morning and thank you all for joining us today to discuss our second quarter 2025 financial results and business updates. With me on the call today are Josh Cohen and Justin Klee, our co-CEOs, Dr. Camille Bedrogian, our Chief Medical Officer, and Jim Fradies, our Chief Financial Officer. Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans, and expectations and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include but are not limited to our expectations with respect to Avexatide, AMX 35, and AMX 114, statements regarding regulatory and clinical developments, the impact thereof and the expected timing thereof, and statements regarding our cash runway. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. You are cautioned not to place any undue reliance on these forward-looking statements, and AMLX disclaims any obligation to update such statements unless required by law. Now I will turn the call over to Justin.